ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Plus Therapeutics, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of -3.20% over the last 5 years
3
The company declared very negative results in Mar'25 after flat results in Dec'24
- INTEREST(HY) At USD 3.76 MM has Grown at 6,062.3%
- OPERATING CASH FLOW(Y) Lowest at USD -16.86 MM
- NET SALES(HY) At USD 2.45 MM has Grown at -17.15%
4
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -54.41%, its profits have fallen by -100.8%
5
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -54.41% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Plus Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Plus Therapeutics, Inc.
-51.12%
-0.19
398.72%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-3.20%
EBIT Growth (5y)
-198.96%
EBIT to Interest (avg)
-9.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.42
Sales to Capital Employed (avg)
-0.66
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.28%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.45
EV to EBIT
-0.06
EV to EBITDA
-0.06
EV to Capital Employed
-0.03
EV to Sales
0.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
NET PROFIT(HY)
Higher at USD -13.58 MM
RAW MATERIAL COST(Y)
Fallen by -11.54% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -225.74 %
OPERATING PROFIT(Q)
Highest at USD -1.45 MM
OPERATING PROFIT MARGIN(Q)
Highest at -104.46 %
PRE-TAX PROFIT(Q)
Highest at USD -1.36 MM
EPS(Q)
Highest at USD -0.01
-14What is not working for the Company
INTEREST(HY)
At USD 3.76 MM has Grown at 6,062.3%
OPERATING CASH FLOW(Y)
Lowest at USD -16.86 MM
NET SALES(HY)
At USD 2.45 MM has Grown at -17.15%
NET PROFIT(HY)
At USD -13.58 MM has Grown at -24.64%
Here's what is working for Plus Therapeutics, Inc.
Net Profit
Higher at USD -13.58 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Profit
Highest at USD -1.45 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -104.46 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -1.36 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -1.36 MM has Grown at 76.96%
over average net sales of the previous four periods of USD -5.91 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
EPS
Highest at USD -0.01
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -225.74 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -11.54% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Plus Therapeutics, Inc.
Interest
At USD 3.76 MM has Grown at 6,062.3%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Net Sales
At USD 2.45 MM has Grown at -17.15%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Net Profit
At USD -13.58 MM has Grown at -24.64%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Operating Cash Flow
Lowest at USD -16.86 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
